Description,Qualitative Measure,Measurement Inequality,Quantitative measurement,Units,Allele Name,MHC allele class,Ref Type,Ref Date,Ref Title,Assay Method,Assay Group,Host Name,Description_Length,Normalized_QM
KLVVVGAVGV,Positive,=,35810.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0308505232402733
LLVVGAAGV,Positive,=,17540.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.096817050308088
LLVVGARGV,Positive,=,23700.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0689984524324982
LLVVGAVGV,Positive,=,25560.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0620155384224109
LLVVVGARGV,Positive-High,=,6550.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.1878557861679665
YLVVGAAGV,Positive,=,16410.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1029718050629049
YLVVGACGV,Positive,=,26090.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0601186908993082
YLVVGADGV,Positive,=,13420.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1215622759830237
YLVVGARGV,Positive,=,15600.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1076502734673309
YLVVGASGV,Positive,=,21170.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0794321193734345
YLVVGAVGV,Positive,=,22950.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0719705199545163
YLVVVGAAGV,Positive,=,27740.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0544509855058985
YLVVVGADGV,Positive-High,=,5683.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.2009785862475908
YLVVVGASGV,Positive,=,10650.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.142929279382826
YLVVVGAVGV,Positive,=,15470.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.1084236950154021
YVVVGAVGV,Positive,=,28260.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0527345027941913
EAAGIGILTV,Positive,,22500.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.0738007448237922
SLLMWITQC,Positive,,4450.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2235830389182367
EAAGIGILTVI,Positive,,30700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),11,0.0450804386202429
ELAGIGILTV,Positive,,2480.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2776179295262677
EMAGIGILTV,Positive,,3600.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2431740365472272
EIAGIGILTV,Positive,,3350.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2498260674607251
EVAGIGILTV,Positive,,4210.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2287071225201845
ELAGIGILTL,Positive,,4170.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2295894522345869
ELAGIGILTA,Positive,,5610.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.202173485296401
ELAGIGILTI,Positive,,2930.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2622069055229073
ELAGIGILTM,Positive,,36800.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.0283300777701626
EMAGIGILTL,Positive,,4380.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2250484452669637
EMAGIGILTA,Positive,,3620.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2426619945968299
EMAGIGILTI,Positive,,1790.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.3077519056350024
EMAGIGILTM,Positive,,37500.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.0265885367416714
SLLMWITQA,Positive,,1090.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3535973851423163
SLLMWITQL,Positive,,1970.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2988960935861278
SLLMWITQV,Positive,,1190.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3454848703961633
SLLMWITQM,Positive,,2380.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2814218958748952
SLLMWITQI,Positive,,1360.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3331434536762918
SALMWITQA,Positive,,2280.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2853891716904157
SALMWITQL,Positive,,1990.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2979625166013703
SALMWITQV,Positive,,1700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3125197823358424
SALMWITQM,Positive,,11400.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1366395513074301
SALMWITQI,Positive,,2030.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2961231855361516
SMLMWITQA,Positive,,950.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3663029126508308
SMLMWITQL,Positive,,1340.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3345127133224426
SMLMWITQV,Positive,,1010.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3606425725190039
SMLMWITQM,Positive,,1570.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3198723019171888
SMLMWITQI,Positive,,710.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3932163120666763
SILMWITQA,Positive,,1920.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3012721456672733
SILMWITQL,Positive,,5420.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2053579224611342
SILMWITQV,Positive,,1060.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3561768084339461
SILMWITQM,Positive,,3100.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2569942581858182
SILMWITQI,Positive,,2700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2697625732888986
GILGFVFTL,Positive,,1020.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3597319904179632
LLAAPSAMA,Positive-Intermediate,,37120.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0275298707312079
AAVTSQFPV,Positive-Intermediate,,27710.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0545509927318653
LMAVEEREV,Positive-Intermediate,,34110.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0353456788988569
GLMKGGANL,Positive-Intermediate,,16990.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.099761570096086
MLREQLDQV,Positive-Intermediate,,13870.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1185139600271665
TLHGFVNHI,Positive-Intermediate,,10650.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.142929279382826
RILSCLSDL,Positive-Intermediate,,29320.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0493312445393411
GLLHKVKEL,Positive-Intermediate,,30140.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0467819024498046
ALLVVSREL,Positive-High,,5522.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.2036347542439748
WLAKTRVFL,Positive-High,,5871.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1979706027278215
ILCKDLSTV,Positive-High,,9327.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1551889088247557
FLTDVACRV,Positive-High,,5380.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.2060425428926392
AVLERYLEL,Positive-High,,5962.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1965490377225576
MQSLHFAFL,Positive-Intermediate,,47660.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0044298998091865
ALEAVRIEL,Positive-High,,5843.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1984124429748287
TLHDIWPEI,Positive-High,,9314.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1553178185997878
GLYDVQLTI,Positive-Intermediate,,31720.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0420596057238248
ALLSNDNAL,Positive-High,,8692.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1617057112487147
LLPMSLHWFI,Positive-Intermediate,,38820.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0233911842770331
LLFAKFSFLI,Positive-Intermediate,,19150.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0887005504710117
RQLLFSLLAV,Positive-Intermediate,,24610.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0655161429737021
SLNVDTAFPL,Positive-Intermediate,,45060.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0096146212694522
TLAGHVYEYI,Positive-Intermediate,,48080.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0036189942318516
KLIASILYQA,Positive-Intermediate,,16220.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.1040481539592138
FLIHSSTGLI,Positive-Intermediate,,39570.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0216226011181674
GILGFVFTL,Positive-High,,7048.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1810831114365163
YLQPRTFLL,Positive,,75.0,nM,HLA-A*02:01,I,Literature,2023,Coarse-grained molecular dynamics-guided immunoinformatics to explain the binder and non-binder classification of Cytotoxic T-cell epitope for SARS-CoV-2 peptide-based vaccine discovery.,binding assay,dissociation constant KD,Homo sapiens (human),9,0.6009633469331641
GLYPQLSAI,Positive,,5.9,nM,HLA-A*02:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8359529831152714
QLSAIALGV,Positive,,3.9,nM,HLA-A*02:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8742140072226278
